Publications by authors named "Katelin Baird"
Article Synopsis
- - Outcomes for patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) are generally poor; however, the FDA approved Loncastuximab-teserine (Lonca) based on the LOTIS-2 trial results for those who have undergone at least two prior treatments.
- - A retrospective study analyzed 187 patients from 21 US centers treated with Lonca, revealing a complete response rate of 14% and an overall response rate of 32%, indicating lower efficacy in a real-world setting compared to the original trial.
- - Patients in this study had higher risk features, including bulky disease and high-grade B-cell histology, leading to poorer median event-free survival (2.1 months
In the pivotal study ECHELON-1, brentuximab vedotin (BV), doxorubicin, vinblastine, and dacarbazine (A + AVD) demonstrated superior efficacy compared with bleomycin + AVD for the treatment of advanced-stage classic Hodgkin lymphoma (cHL). However, there are minimal available data regarding the frequency of dose reductions or omission of BV during curative therapy and the potential impact on patient outcomes. In a real-world analysis, we retrospectively reviewed the characteristics and outcomes of 179 patients with stage III or IV cHL treated with frontline A + AVD from January 2010 to April 2022.
View Article and Find Full Text PDFIntroduction: Visceral involvement of cutaneous T-cell lymphoma (vCTCL) is a rare but poorly studied complication of CTCL. We aimed to assess clinical characteristics, treatment, and outcomes, associated with vCTCL at our institution.
Methods: We conducted a retrospective review of patients with vCTCL among patients with a confirmed histopathologic diagnosis of CTCL seen at the Winship Cancer Institute in Emory University.
Non-Hodgkin lymphoma and chronic lymphocytic leukemia (NHL/CLL) patients elicit inadequate antibody responses after initial SARS-CoV-2 vaccination and remain at high risk of severe COVID-19 disease. We investigated IgG, IgA, and IgM responses after booster vaccination against recent SARS-CoV-2 variants including Omicron BA.5 in 67 patients.
View Article and Find Full Text PDFBackground: Risk factors for progression to advanced-stage mycosis fungoides (MF) are poorly defined.
Methods: The authors performed a single-center, retrospective cohort study among patients with MF at an academic medical center from 1990 to 2020 to identify clinical variables associated with progression to advanced-stage MF (stage IIB-IVB), and 388 patients who had a clinicopathologic diagnosis of early stage (IA-IIA) MF were identified from their cutaneous lymphoma database. Baseline clinical characteristics, laboratory values, imaging, and blood flow cytometry or T-cell receptor gene rearrangement (TCR) data were collected.
Objective: To evaluate the response of incidentally discovered pituitary cysts to growth hormone (GH) treatment.
Methods: A retrospective chart review was performed of children with pituitary cysts on magnetic resonance imaging (MRI) over a 5-year period. Records and images were reviewed, and the results were analyzed using descriptive statistics.